arXiv Machine Learning

OpenTumorBoard: A Real-World Benchmark of Multidisciplinary Tumor Board Discussion Trajectories

arXiv AI
Sep 2

Towards AI-Assisted Clinical Trial Matching: Practical Considerations, Multicenter Evaluation, and Real-World Deployment

arXiv:2609.01202v1 Announce Type: cross Abstract: Clinical trials are essential for advancing cancer care and drug development, but many fail because of insufficient patient enrollment. While there i...

By Yin Fang, Qiao Jin, Shubo Tian, Lauren He, Maya Geer, Noor Naffakh, Ryan Huu-Tuan Nguyen, Zifeng Wang, Jimeng Sun, Charalampos S. Floudas, James L. Gulley, Kamilia Moalem, Catarina Martins Maia, Amanda Nottke, Juan W. Valle, Melinda Bachini, Lourdes Rocha-Nussbaum, Kari Ramage, Nikita Curry, Megan Barnes, Mandy Mansaray, Darlene Gabeau, Craig E. Grossman, Heath Skinner, Michael Burczynski, NIH-TrialBench Consortium, Zhiyong Lu
arXiv Machine Learning
Jun 2

OncoReason: Structuring Clinical Reasoning in LLMs for Robust and Interpretable Survival Prediction

arXiv:2510. 17532v2 Announce Type: replace-cross Abstract: Predicting cancer treatment outcomes requires models that are both accurate and interpretable, particularly in the presence of heterogeneous clinical data.

By Raghu Vamshi Hemadri, Geetha Krishna Guruju, Kristi Topollai, Anna Ewa Choromanska
arXiv AI
Oct 2

OpenMTB-Audit: Exposing Over-Refusal and Clinical Expert Perspectives in LLM-Based Molecular Tumor Board Safety Evaluation

OpenMTB‑Audit is an open‑source benchmark that tests large language models on 500 synthetic non‑small cell lung cancer cases, covering five adversarial error categories and four safety labels: Supported, Partially Supported, Unsupported, and Insufficient Information. The study found that all eight tested LLMs over‑refused Partially Supported recommendations, collapsing labels to achieve high safety scores. A deterministic seven‑module framework, MTB‑AuditAgent, was introduced to reduce over‑refusal to 6.7% and reach 91.2% accuracy, while an oncologist annotation study highlighted disagreement around the boundary between information sufficiency and treatment optimization.

By Negin Ashrafi, Jia Luo, Stacey M. Frumm, Roxana Daneshjou
arXiv AI
Sep 15

ClinAgent: A ReAct-Based Agent for Conversational Access to Clinical Trial Information

ClinAgent is a conversational system that uses a ReAct-based LLM agent to retrieve and synthesize clinical trial information from multiple sources such as ClinicalTrials.gov, PubMed, and a local dataset. The agent iteratively reasons over user queries, selects appropriate tools, and refines its actions to provide grounded, up-to-date responses in natural language across multi-turn interactions. Evaluation across three phases shows that DeepSeek (thinking mode) excels in planning quality while Gemini 3.0 Flash delivers the highest overall performance and expert ratings, demonstrating the promise of agentic AI for improving clinical trial data access.

By Antonino Vaccarella, Riccardo Cantini, Domenico Talia, Paolo Trunfio, Marianna Talia, Rosamaria Lappano, Marcello Maggiolini